Contentious Indian Pricing Orders Now In Court
This article was originally published in Scrip
Executive Summary
A string of controversial price-related orders by India's National Pharmaceutical Pricing Authority (NPPA) are believed to have been challenged in court, putting plans to enforce these rules in limbo, at least in specific cases.
You may also be interested in...
Court Stays Controversial Indian Price Freeze
The Bombay High Court has stayed certain controversial price-related orders by India's National Pharmaceutical Pricing Authority (NPPA), including one pertaining to transitioning "non-scheduled" medicines, as the pharmaceutical industry contests multiple regulatory changes in India.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.